Search research articles
Contact Us
Filters
Showing results (91-100 of 283) with videos related to
Page
of 29
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
June 10, 2025
Blood-Based Measurable Residual Disease by Clonotypic Mass Spectrometry is Prognostic in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant
Michael J Slade, Julie Fortier, Abir Khaled, et al.
Cancer Cell
|
April 17, 2014
Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4
Han Liu, Todd D Westergard, Amanda Cashen, et al.
JCO Oncology Practice
|
May 12, 2025
High-Deductible Health Plans and Out-of-Pocket Health Care Costs Among Younger Patients With Multiple Myeloma
Mark Aaron Fiala, Mengmeng Ji, Michael Slade, et al.
Frontiers in Immunology
|
August 10, 2023
Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM
Sandy Wong, Habib Hamidi, Luciano J Costa, et al.
The Oncologist
|
November 10, 2017
Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies
Rami Komrokji, Arlene S Swern, David Grinblatt, et al.
Haematologica
|
March 24, 2018
Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow
Dhruv Bansal, Kiran Vij, Gue Su Chang, et al.
Haematologica
|
January 19, 2019
PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma
Barbara Muz, Maurizio Buggio, Feda Azab, et al.
Scientific Reports
|
September 30, 2021
A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma
Kinan Alhallak, Amanda Jeske, Pilar de la Puente, et al.
Leukemia Research
|
August 7, 2010
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902
Richard M Stone, Barry Moser, Ben Sanford, et al.
British Journal of Clinical Pharmacology
|
May 20, 2014
Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance)
Xiaofeng Wang, Kouros Owzar, Pankaj Gupta, et al.
Page
of 29
Search research articles
Search
Showing results (91-100 of 283) with videos related to
Sort By:
Page
of 29
Clinical Lymphoma, Myeloma & Leukemia
|
June 10, 2025
Blood-Based Measurable Residual Disease by Clonotypic Mass Spectrometry is Prognostic in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant
Michael J Slade, Julie Fortier, Abir Khaled, et al.
Cancer Cell
|
April 17, 2014
Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4
Han Liu, Todd D Westergard, Amanda Cashen, et al.
JCO Oncology Practice
|
May 12, 2025
High-Deductible Health Plans and Out-of-Pocket Health Care Costs Among Younger Patients With Multiple Myeloma
Mark Aaron Fiala, Mengmeng Ji, Michael Slade, et al.
Frontiers in Immunology
|
August 10, 2023
Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM
Sandy Wong, Habib Hamidi, Luciano J Costa, et al.
The Oncologist
|
November 10, 2017
Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies
Rami Komrokji, Arlene S Swern, David Grinblatt, et al.
Haematologica
|
March 24, 2018
Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow
Dhruv Bansal, Kiran Vij, Gue Su Chang, et al.
Haematologica
|
January 19, 2019
PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma
Barbara Muz, Maurizio Buggio, Feda Azab, et al.
Scientific Reports
|
September 30, 2021
A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma
Kinan Alhallak, Amanda Jeske, Pilar de la Puente, et al.
Leukemia Research
|
August 7, 2010
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902
Richard M Stone, Barry Moser, Ben Sanford, et al.
British Journal of Clinical Pharmacology
|
May 20, 2014
Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance)
Xiaofeng Wang, Kouros Owzar, Pankaj Gupta, et al.
Page
of 29